Chronic inflammatory response syndrome: a review of the evidence of clinical efficacy of treatment.
Dooley, Ming, Vukelic, April, Jim, Lysander · Annals of medicine and surgery (2012) · 2024 · DOI
Quick Summary
This review looked at studies about treatments for conditions involving long-term inflammation and fatigue, including ME/CFS. The researchers found that most published studies focused on a treatment approach called the Shoemaker Protocol, which was reported to work better than other treatments tested. However, this review only examined existing published articles rather than conducting new research, so the strength of the evidence depends heavily on the quality of those original studies.
Why It Matters
This review addresses the overlap and distinction between ME/CFS and CIRS diagnoses, which often creates confusion in clinical practice and delays appropriate treatment. Understanding available evidence for treatments may help patients and clinicians make informed decisions, particularly given that ME/CFS remains poorly understood with no established standard treatment. The findings suggest a specific protocol may warrant further investigation in properly controlled trials.
Observed Findings
Only 13 published articles on CIRS treatment efficacy were identified in the literature.
The Shoemaker Protocol appeared in 11 of the 13 CIRS treatment articles reviewed.
Twenty-two articles addressed ME/CFS treatment, indicating broader research attention to this condition.
The Shoemaker Protocol reportedly demonstrated superior outcomes compared to ME/CFS treatment protocols in available literature.
ME/CFS remains a common misdiagnosis for CIRS despite lack of defined etiology or biomarkers.
Inferred Conclusions
The Shoemaker Protocol is the most frequently reported and documented treatment for CIRS in published literature.
CIRS and ME/CFS are often conflated despite potentially distinct etiologies (environmental exposure vs. undefined cause).
Current treatment options for ME/CFS in published literature lack the documented efficacy shown for CIRS treatments.
The field lacks sufficient high-quality evidence to establish definitive treatment protocols for either condition.
Remaining Questions
Has the Shoemaker Protocol been rigorously tested in double-blind, placebo-controlled randomized trials with adequate sample sizes?
What This Study Does Not Prove
This review does not prove the Shoemaker Protocol is definitively effective, as it only synthesizes existing published literature without conducting new clinical trials or rigorous comparative studies. The review cannot establish whether CIRS and ME/CFS are distinct conditions or represent different manifestations of the same underlying illness. Publication bias may have inflated apparent efficacy of reported treatments, as negative studies are less likely to be published.
Are CIRS and ME/CFS mechanistically distinct conditions, and do they require different treatment approaches?
Why is there such a stark difference in published treatment literature between CIRS (13 articles) and ME/CFS (22 articles) despite potential diagnostic overlap?
What are the long-term outcomes and safety profile of the Shoemaker Protocol across diverse patient populations?